FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:1848-1850 December 17, 1998 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Cohn, J. N. PubMed Citation

Looking back reveals how the direction of therapy for heart failure has changed since the inception of the first large clinical trial of vesnarinone, an inotropic agent, in April 1990. At that time, many investigators remained interested in the concept of heart failure as a defect that could be remedied by drugs that enhanced cardiac contractility.¹ Intravenous dopamine and dobutamine were widely used to increase cardiac output with less chronotropy and fewer arrhythmias than the more potent adrenergic agonists isoproterenol, epinephrine, and norepinephrine. Even though excess mortality was found with long-term outpatient infusions of dobutamine and the oral sympathomimetic amines . . . [Full Text of this Article]

References

Related Letters:

Chronic Heart Failure and the Quality of Life
Pritzker M. R., Alhaddad I. A., Cohn J. N.
Extract | Full Text  
N Engl J Med 1999; 340:1511-1512, May 13, 1999. Correspondence

This article has been cited by other articles:

• Hoshijima, M., Knoll, R., Pashmforoush, M., Chien, K. R. (2006). Reversal of Calcium Cycling Defects in Advanced Heart Failure: Toward Molecular Therapy. J Am Coll Cardiol 48: A15-A23 [Abstract] [Full Text]  
• Sheikh-Taha, M. (2005). Intermittent nesiritide therapy in outpatients with chronic heart failure. Am J Health Syst Pharm 62: 196-198 [Full Text]  
• del Monte, F., Hajjar, R. J (2003). Targeting calcium cycling proteins in heart failure through gene transfer. J. Physiol. 546: 49-61 [Abstract] [Full Text]  
• Cowie, M.R. (2002). The fine art of prognostication. Eur Heart J 23: 1804-1806 [Full Text]  
• Al-Hesayen, A., Azevedo, E. R., Newton, G. E., Parker, J. D. (2002). The effects of dobutamine on cardiac sympathetic activity in patients with congestive heart failure. J Am Coll Cardiol 39: 1269-1274 [Abstract] [Full Text]  
• HOSHIJIMA, M., PASHMFOROUSH, M., KNOLL, R., CHIEN, K.R. (2002). The MLP Family of Cytoskeletal Z Disc Proteins and Dilated Cardiomyopathy: A Stress Pathway Model for Heart Failure Progression. Cold Spring Harb Symp Quant Biol 67: 399-408 [Abstract]  
• del Monte, F., Williams, E., Lebeche, D., Schmidt, U., Rosenzweig, A., Gwathmey, J. K., Lewandowski, E. D., Hajjar, R. J. (2001). Improvement in Survival and Cardiac Metabolism After Gene Transfer of Sarcoplasmic Reticulum Ca2+-ATPase in a Rat Model of Heart Failure. Circulation 104: 1424-1429 [Abstract] [Full Text]  
• Torre-Amione, G., Durand, J.-B., Nagueh, S., Vooletich, M. T., Kobrin, I., Pratt, C. (2001). A Pilot Safety Trial of Prolonged (48 h) Infusion of the Dual Endothelin-Receptor Antagonist Tezosentan in Patients With Advanced Heart Failure. Chest 120: 460-466 [Abstract] [Full Text]  
• Torre-Amione, G., Young, J. B., Durand, J.-B., Bozkurt, B., Mann, D. L., Kobrin, I., Pratt, C. M. (2001). Hemodynamic Effects of Tezosentan, an Intravenous Dual Endothelin Receptor Antagonist, in Patients With Class III to IV Congestive Heart Failure. Circulation 103: 973-980 [Abstract] [Full Text]  
• Hajjar, R. J., del Monte, F., Matsui, T., Rosenzweig, A. (2000). Prospects for Gene Therapy for Heart Failure. Circ. Res. 86: 616-621 [Abstract] [Full Text]  
• del Monte, F., Harding, S. E., Schmidt, U., Matsui, T., Kang, Z. B., Dec, G. W., Gwathmey, J. K., Rosenzweig, A., Hajjar, R. J. (1999). Restoration of Contractile Function in Isolated Cardiomyocytes From Failing Human Hearts by Gene Transfer of SERCA2a. Circulation 100: 2308-2311 [Abstract] [Full Text]  
• Sin, D. D., Bradley, T. D. (1999). Theophylline Therapy for Near-Fatal Cheyne-Stokes Respiration. ANN INTERN MED 131: 713-713 [Full Text]  
• Stevenson, L. W. (1999). Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail 1: 251-257 [Full Text]  
• Pritzker, M. R., Alhaddad, I. A., Cohn, J. N. (1999). Chronic Heart Failure and the Quality of Life. NEJM 340: 1511-1512 [Full Text]  
• (1999). Vesnarinone Reduces Symptoms but Increases Mortality. Journal Watch Cardiology 1999: 1-1 [Full Text]